The potential benefits of GLP-1 medications continue to expand. New research has found that the weight loss and diabetes drugs — officially known as glucagon-like peptide 1 receptor agonists — are ...

UROTHELIAL bladder cancer (UBC) accounts for around 90% of urinary tract malignancies and remains one of the most common cancers worldwide. Despite advances in surgery, chemotherapy, and radiotherapy, ...

JCO Precision Oncology Conversations features discussions with leading authors of JCO Precision Oncology articles, hosted by Dr. Abdul Rafeh Naqash. Join our experts in engaging conversations as they ...

A New Jersey veteran diagnosed with an aggressive cancer has surprised his own doctors, and now his case could give hope to other patients. In December 2024, at age 97, Mountainside resident Teddy ...

(UroToday.com) The 2025 Interdisciplinary Genitourinary Cancer Forum featured a metastatic urothelial carcinoma session and a presentation by Dr. Daniel Petrylak discussing the optimal sequence of ...

IDE397 and sacituzumab govitecan combination shows a 57% response rate in MTAP-deletion urothelial cancer at dose level 2. Safety profiles at both dose levels are manageable, with no serious treatment ...

Urothelial carcinoma (UC) is the second most common genitourinary cancer, leading to over 16,000 deaths a year in the United States. Despite recent advances, the 5-year survival rate for metastatic UC ...

Judy Wells traveled to MSK from Mississippi to be treated for late-stage urothelial carcinoma of the kidney, using a new approach that included an antibody-drug conjugate. A few months later, scans ...

IDE397 combined with sacituzumab govitecan showed promising efficacy in MTAP-deletion urothelial carcinoma, with high disease control rates in both dose cohorts. The combination therapy's efficacy ...

Schematic representation of the study workflow. ICD-O-3, International Classification of Disease for Oncology, third edition; IPC, initial prostate cancer; OS, overall survival; PCa, prostate cancer; ...

1Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, Canada. 2Department of Medical Oncology, BC Cancer, Vancouver ...

Prostate cancer is among the most common cancers in men and a leading cause of cancer-related deaths. With improved detection and therapies, survival rates have risen, but this progress comes with a ...